CYC
Cyclopharm Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💰
0.67%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
3
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The firm specializes in functional lung ventilation imagery. The principal activities of the Company include manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of third-party products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The company distributes its products under the name Technegas in over 60 countries across the world with approximately 1500 nuclear medicine departments. The company also focuses on commercializing its Ultralute technology.
📈 Performance
Price History
+1021.09%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
0.67%
💰 Annual Dividend Earnings Per $1,000 invested**
$6.69
💰 Most Recent Dividend Franked Percentage Estimate
0.00%
💰 Average Dividend Franked Percentage Estimate
82.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.01
0.00%
2021
$0.01
0.00%
2020
$0.01
0.00%
2019
$0.01
0.00%
2018
$0.01
0.00%
2017
$0.01
0.00%
2016
$0.01
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$2.00
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CYC
3
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in CYC
698 days
CYC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
60%
50k - 100k
20%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
33%
35 - 90
67%
🙋 Legal gender of investors
Female
33%
Male
67%
Pearlers who invest in CYC also invest in...
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 234 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.
📊 Share price
$11.55 AUD
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
Lynas Rare Earths Ltd. engages in the production of rare earth minerals. The company is headquartered in Kuantan, Pahang. The Company’s assets include Mt Weld, Lynas Malaysia, Kalgoorlie and Lynas USA. Mt Weld is a rare earth mine, located approximately 35-kilometer (km) south of Laverton in Western Australia. Lynas Malaysia is an integrated manufacturing facility, separating and processing rare earths materials, located in the Gebeng Industrial Estate near the Port of Kuantan in Malaysia. Kalgoorlie is a rare earth processing facility, which is located in the Western Australia. Its subsidiaries include Lynas Malaysia Sdn Bhd, Lynas Services Pty Ltd, Mount Weld Holdings Pty Ltd, Mount Weld Mining Pty Ltd, and Lynas Kalgoorlie Pty Ltd.
📊 Share price
$7.65 AUD
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
📊 Share price
$29.97 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL THEMATIC
Want more shares? Try these...
